Table 1: Univariate analysis of demographic and clinical characteristics of non-rebleeding and rebleeding patients.

VariablesNon-rebleeding group ( )Rebleeding group ( )P-value

Age (years) 0.941
Female gender, (%)50 (28.2)21 (48.8)0.010*
Creatinine (mg/dL) <0.001*
Hb (g/L) 0.074
Platelet (×109/L) 0.113
Use of NSAIDs, (%)12 (6.8)2 (4.7)0.608
Use of aspirin, (%)31 (17.5)1 (2.3)0.011*
Use of clopidogrel, (%)18 (10.2)5 (11.6)0.779
Use of warfarin, (%)7 (4.0)3 (7.0)0.393
Coexisting illness, (%)
 CKD III to V73 (41.2)26 (60.5)0.013*
 COPD6 (3.4)5 (11.6)0.026*
 CAD29 (16.4)8 (18.6)0.727
 DM48 (27.1)18 (41.9)0.058
 CVA26 (14.7)8 (18.6)0.524
 Liver cirrhosis32 (18.1)7 (16.3)0.782
High stigmata, (%)173 (97.7)41 (95.3)0.388
Forrest classification Ia/Ib/IIa/IIb/IIc/III9/100/18/45/5/05/31/1/5/0/1
Shock on admission, (%)89 (50.3)23 (53.5)0.706
Rockall score , (%)105 (59.3)36 (83.7)0.003*
Time to endoscope (h) 0.129
Hemostasis methods A/B/C/D/E/F62/48/11/50/2/411/14/0/15/2/1
Ulcer size (cm) 0.973
Multiple ulcers, (%)58 (32.8)18 (41.9)0.261
PRBC BT (mL) <0.001*
Surgery, (%)02 (4.7)0.004*
Hospital stay (days) <0.001*
Mortality, (%)8 (4.5)9 (20.9)0.001*
Bleeding related/other causes1/73/6

PPI: proton-pump inhibitors, Hb: hemoglobin, CKD: chronic kidney disease, NSAID: nonsteroidal anti-inflammatory drug, PPI: proton-pump inhibitor, DM: diabetes mellitus type 2, COPD: chronic obstructive pulmonary disease, CAD: coronary artery disease, CVA: cerebrovascular accident, BT: blood transfusion, PPI: proton pump inhibitor, Hemostasis methods A/B/C/D/E/F: Bosmin plus APC/heat probe=A, APC/heat probe=B, Hemoclip=C, Bosmin plus hemoclip=D, APC/heat probe plus hemoclip=E, APC plus hemoclip plus Bosmin=F, APC: argon plasma coagulation. * .